Filing Details
- Accession Number:
- 0001104659-23-008873
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-31 21:50:16
- Reporting Period:
- 2023-01-29
- Accepted Time:
- 2023-01-31 21:50:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1709401 | Rubius Therapeutics Inc. | RUBY | Biological Products, (No Disgnostic Substances) (2836) | 042688109 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1800952 | A. Laurence Turka | C/O Rubius Therapeutics, Inc. 399 Binney St., Suite 300 Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-29 | 7,438 | $0.00 | 12,359 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-01-31 | 8,625 | $0.00 | 20,984 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-31 | 2,593 | $0.24 | 18,391 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2023-01-29 | 7,438 | $0.00 | 7,438 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-01-31 | 8,625 | $0.00 | 8,625 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,874 | No | 4 | M | Direct | ||
| 25,875 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
- The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
- The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.
Billionaire Hedge Funds
